Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 117 entries
Sorted by: Best Match Show Resources per page
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.

Pulmonary circulation

Lajoie AC, Bonnet S, Provencher S.
PMID: 28597774
Pulm Circ. 2017 Apr-Jun;7(2):312-325. doi: 10.1177/2045893217710639. Epub 2017 May 30.

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by a progressive increase in pulmonary vascular resistance, ultimately leading to right heart failure and death. Throughout the past 20 years, numerous specific pharmacologic agents, including phosphodiesterase-5 inhibitors, endothelin receptor...

Cite
Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ. 2017;7(2):312-325doi: 10.1177/2045893217710639.
Lajoie, A. C., Bonnet, S., & Provencher, S. (2017). Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary circulation, 7(2), 312-325. https://doi.org/10.1177/2045893217710639
Lajoie, Annie-Christine, et al. "Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges." Pulmonary circulation vol. 7,2 (2017): 312-325. doi: https://doi.org/10.1177/2045893217710639
Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ. 2017 Apr-Jun;7(2):312-325. doi: 10.1177/2045893217710639. Epub 2017 May 30. PMID: 28597774; PMCID: PMC5467950.
Copy Download .nbib Format: NLM
Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension.

Anatolian journal of cardiology

Mutlu Z, Kayıkçıoğlu M, Nalbantgil S, Vuran Ö, Kemal H, Moğulkoç N, Ertürk B, Onay H, Eroğlu Z, Kültürsay H.
PMID: 26645265
Anatol J Cardiol. 2016 Jul;16(7):491-496. doi: 10.5152/AnatolJCardiol.2015.6297. Epub 2015 Sep 15.

OBJECTIVE: Germline mutations in the bone morphogenetic protein receptor type-2 (BMPR2) gene are considered to be a major risk factor for pulmonary arterial hypertension (PAH). BMPR2 mutations have been reported in 10%-20% of idiopathic PAH and in 80% of...

Cite
Mutlu Z, Kayıkçıoğlu M, Nalbantgil S, et al. Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension. Anatol J Cardiol. 2015;16(7):491-496doi: 10.5152/AnatolJCardiol.2015.6297.
Mutlu, Z., Kayıkçıoğlu, M., Nalbantgil, S., Vuran, �. �., Kemal, H., Moğulkoç, N., Ertürk, B., Onay, H., Eroğlu, Z., & Kültürsay, H. (2016). Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension. Anatolian journal of cardiology, 16(7), 491-496. https://doi.org/10.5152/AnatolJCardiol.2015.6297
Mutlu, Zeynep, et al. "Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension." Anatolian journal of cardiology vol. 16,7 (2016): 491-496. doi: https://doi.org/10.5152/AnatolJCardiol.2015.6297
Mutlu Z, Kayıkçıoğlu M, Nalbantgil S, Vuran Ö, Kemal H, Moğulkoç N, Ertürk B, Onay H, Eroğlu Z, Kültürsay H. Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension. Anatol J Cardiol. 2016 Jul;16(7):491-496. doi: 10.5152/AnatolJCardiol.2015.6297. Epub 2015 Sep 15. PMID: 26645265; PMCID: PMC5331396.
Copy Download .nbib Format: NLM
Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.

Cardiology and therapy

Sulica R, Fenton R, Cefali F.
PMID: 26411969
Cardiol Ther. 2015 Dec;4(2):209-18. doi: 10.1007/s40119-015-0046-y. Epub 2015 Sep 28.

INTRODUCTION: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare, life-threatening diseases in which chronically elevated pressure in the pulmonary arteries results in vascular remodeling and right heart failure. Treatment goals are to improve patient functioning,...

Cite
Sulica R, Fenton R, Cefali F. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Cardiol Ther. 2015;4(2):209-18doi: 10.1007/s40119-015-0046-y.
Sulica, R., Fenton, R., & Cefali, F. (2015). Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Cardiology and therapy, 4(2), 209-18. https://doi.org/10.1007/s40119-015-0046-y
Sulica, Roxana, et al. "Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center." Cardiology and therapy vol. 4,2 (2015): 209-18. doi: https://doi.org/10.1007/s40119-015-0046-y
Sulica R, Fenton R, Cefali F. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Cardiol Ther. 2015 Dec;4(2):209-18. doi: 10.1007/s40119-015-0046-y. Epub 2015 Sep 28. PMID: 26411969; PMCID: PMC4675747.
Copy Download .nbib Format: NLM
Endothelin-receptor antagonists: current and future perspectives.

Drug discovery today

Ray A, Hegde LG, Chugh A, Gupta JB.
PMID: 11018597
Drug Discov Today. 2000 Oct 01;5(10):455-464. doi: 10.1016/s1359-6446(00)01557-9.

Despite much effort over recent years to design and develop endothelin-receptor antagonists, these compounds are far from becoming new drug entities. This article will review preclinical data on select endothelin-receptor antagonists as well as clinical data on bosentan, the...

Cite
Ray A, Hegde LG, Chugh A, et al. Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today. 2000;5(10):455-464doi: 10.1016/s1359-6446(00)01557-9.
Ray, A., Hegde, L. G., Chugh, A., & Gupta, J. B. (2000). Endothelin-receptor antagonists: current and future perspectives. Drug discovery today, 5(10), 455-464. https://doi.org/10.1016/s1359-6446(00)01557-9
Ray, et al. "Endothelin-receptor antagonists: current and future perspectives." Drug discovery today vol. 5,10 (2000): 455-464. doi: https://doi.org/10.1016/s1359-6446(00)01557-9
Ray A, Hegde LG, Chugh A, Gupta JB. Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today. 2000 Oct 01;5(10):455-464. doi: 10.1016/s1359-6446(00)01557-9. PMID: 11018597.
Copy Download .nbib Format: NLM
Endothelin receptors as novel targets in tumor therapy.

Journal of translational medicine

Bagnato A, Natali PG.
PMID: 15165288
J Transl Med. 2004 May 27;2(1):16. doi: 10.1186/1479-5876-2-16.

The endotelin (ET) axis, that includes ET-1, ET-2, ET-3, and the ET receptors, ETA and ETB, plays an important physiological role, as modulator of vasomotor tone, tissue differentiation and development, cell proliferation, and hormone production. Recently, investigations into the...

Cite
Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2004;2(1):16doi: 10.1186/1479-5876-2-16.
Bagnato, A., & Natali, P. G. (2004). Endothelin receptors as novel targets in tumor therapy. Journal of translational medicine, 2(1), 16. https://doi.org/10.1186/1479-5876-2-16
Bagnato, Anna, and Natali, Pier Giorgio. "Endothelin receptors as novel targets in tumor therapy." Journal of translational medicine vol. 2,1 (2004): 16. doi: https://doi.org/10.1186/1479-5876-2-16
Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2004 May 27;2(1):16. doi: 10.1186/1479-5876-2-16. PMID: 15165288; PMCID: PMC436068.
Copy Download .nbib Format: NLM
Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials.

Expert opinion on investigational drugs

Haleen SJ, Cheng XM.
PMID: 15989614
Expert Opin Investig Drugs. 1997 May;6(5):475-87. doi: 10.1517/13543784.6.5.475.

Recent clinical and experimental animal trials indicate that endogenously produced endothelin-1 (ET-1) contributes to the abnormal systemic and pulmonary vascular resistance associated with congestive heart failure (CHF) and pulmonary hypertension (PH). In experimental CHF, the chronic blockade of ET-1...

Cite
Haleen SJ, Cheng XM. Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials. Expert Opin Investig Drugs. 1997;6(5):475-87doi: 10.1517/13543784.6.5.475.
Haleen, S. J., & Cheng, X. M. (1997). Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials. Expert opinion on investigational drugs, 6(5), 475-87. https://doi.org/10.1517/13543784.6.5.475
Haleen, S J, and Cheng, X M. "Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials." Expert opinion on investigational drugs vol. 6,5 (1997): 475-87. doi: https://doi.org/10.1517/13543784.6.5.475
Haleen SJ, Cheng XM. Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials. Expert Opin Investig Drugs. 1997 May;6(5):475-87. doi: 10.1517/13543784.6.5.475. PMID: 15989614.
Copy Download .nbib Format: NLM
Anaesthesia management for pulmonary endarterectomy.

Current opinion in anaesthesiology

Demeyere R, Delcroix M, Daenen W.
PMID: 16534319
Curr Opin Anaesthesiol. 2005 Feb;18(1):63-76. doi: 10.1097/00001503-200502000-00011.

PURPOSE OF REVIEW: Options for the surgical treatment of chronic thromboembolic pulmonary hypertension are either lung transplantation or pulmonary endarterectomy. Pulmonary endarterectomy is considered permanently curative and the treatment of choice. The procedure dramatically improves functional status and provides...

Cite
Demeyere R, Delcroix M, Daenen W. Anaesthesia management for pulmonary endarterectomy. Curr Opin Anaesthesiol. 2005;18(1):63-76doi: 10.1097/00001503-200502000-00011.
Demeyere, R., Delcroix, M., & Daenen, W. (2005). Anaesthesia management for pulmonary endarterectomy. Current opinion in anaesthesiology, 18(1), 63-76. https://doi.org/10.1097/00001503-200502000-00011
Demeyere, Roland, et al. "Anaesthesia management for pulmonary endarterectomy." Current opinion in anaesthesiology vol. 18,1 (2005): 63-76. doi: https://doi.org/10.1097/00001503-200502000-00011
Demeyere R, Delcroix M, Daenen W. Anaesthesia management for pulmonary endarterectomy. Curr Opin Anaesthesiol. 2005 Feb;18(1):63-76. doi: 10.1097/00001503-200502000-00011. PMID: 16534319.
Copy Download .nbib Format: NLM
Synthetic approaches to endothelin receptor antagonists in clinical development.

Current opinion in drug discovery & development

Clark WM.
PMID: 19649828
Curr Opin Drug Discov Devel. 1999 Nov;2(6):565-77.

The increasing structural and stereochemical complexity of new drug candidates continues to pose numerous synthetic challenges for pharmaceutical process development. Often the implementation of new methodologies, and/or the novel utilization of existing methodologies becomes an essential aspect of developing...

Cite
Clark WM. Synthetic approaches to endothelin receptor antagonists in clinical development. Curr Opin Drug Discov Devel. 1999;2(6):565-77
Clark, W. M. (1999). Synthetic approaches to endothelin receptor antagonists in clinical development. Current opinion in drug discovery & development, 2(6), 565-77.
Clark, W M. "Synthetic approaches to endothelin receptor antagonists in clinical development." Current opinion in drug discovery & development vol. 2,6 (1999): 565-77.
Clark WM. Synthetic approaches to endothelin receptor antagonists in clinical development. Curr Opin Drug Discov Devel. 1999 Nov;2(6):565-77. PMID: 19649828.
Copy Download .nbib Format: NLM
Chronic thromboembolic pulmonary hypertension: Medical treatment.

Pulmonary circulation

Ozsu S, Cinarka H.
PMID: 24015333
Pulm Circ. 2013 Apr;3(2):341-4. doi: 10.4103/2045-8932.114761.

Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the...

Cite
Ozsu S, Cinarka H. Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulm Circ. 2013;3(2):341-4doi: 10.4103/2045-8932.114761.
Ozsu, S., & Cinarka, H. (2013). Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulmonary circulation, 3(2), 341-4. https://doi.org/10.4103/2045-8932.114761
Ozsu, Savas, and Cinarka, Halit. "Chronic thromboembolic pulmonary hypertension: Medical treatment." Pulmonary circulation vol. 3,2 (2013): 341-4. doi: https://doi.org/10.4103/2045-8932.114761
Ozsu S, Cinarka H. Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulm Circ. 2013 Apr;3(2):341-4. doi: 10.4103/2045-8932.114761. PMID: 24015333; PMCID: PMC3757827.
Copy Download .nbib Format: NLM
Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.

International journal of rheumatology

Arefiev K, Fiorentino DF, Chung L.
PMID: 22121371
Int J Rheumatol. 2011;2011:201787. doi: 10.1155/2011/201787. Epub 2011 Oct 27.

Systemic sclerosis is a connective tissue disease characterized by fibrosis of the skin, internal organs, and widespread vasculopathy. Raynaud's phenomenon and digital ulcers are vascular manifestations of this disease and cause significant morbidity. Current treatments are only moderately effective...

Cite
Arefiev K, Fiorentino DF, Chung L. Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. Int J Rheumatol. 2011;2011:201787doi: 10.1155/2011/201787.
Arefiev, K., Fiorentino, D. F., & Chung, L. (2011). Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. International journal of rheumatology, 2011201787. https://doi.org/10.1155/2011/201787
Arefiev, Kait, et al. "Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis." International journal of rheumatology vol. 2011 (2011): 201787. doi: https://doi.org/10.1155/2011/201787
Arefiev K, Fiorentino DF, Chung L. Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. Int J Rheumatol. 2011;2011:201787. doi: 10.1155/2011/201787. Epub 2011 Oct 27. PMID: 22121371; PMCID: PMC3205679.
Copy Download .nbib Format: NLM
Pulmonary Arterial Hypertension: Pathophysiology and Treatment.

Diseases (Basel, Switzerland)

Lan NSH, Massam BD, Kulkarni SS, Lang CC.
PMID: 29772649
Diseases. 2018 May 16;6(2). doi: 10.3390/diseases6020038.

Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a chronic and progressive disorder characterised by angioproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation and thrombosis. These changes increase...

Cite
Lan NSH, Massam BD, Kulkarni SS, et al. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Diseases. 2018;6(2)doi: 10.3390/diseases6020038.
Lan, N. S. H., Massam, B. D., Kulkarni, S. S., & Lang, C. C. (2018). Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Diseases (Basel, Switzerland), 6(2), . https://doi.org/10.3390/diseases6020038
Lan, Norris S H, et al. "Pulmonary Arterial Hypertension: Pathophysiology and Treatment." Diseases (Basel, Switzerland) vol. 6,2 (2018). doi: https://doi.org/10.3390/diseases6020038
Lan NSH, Massam BD, Kulkarni SS, Lang CC. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Diseases. 2018 May 16;6(2). doi: 10.3390/diseases6020038. PMID: 29772649; PMCID: PMC6023499.
Copy Download .nbib Format: NLM
Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Frontiers in pharmacology

Alencar AKN, Montes GC, Barreiro EJ, Sudo RT, Zapata-Sudo G.
PMID: 29255415
Front Pharmacol. 2017 Dec 04;8:858. doi: 10.3389/fphar.2017.00858. eCollection 2017.

Pulmonary arterial hypertension (PAH) is a clinical condition characterized by pulmonary arterial remodeling and vasoconstriction, which promote chronic vessel obstruction and elevation of pulmonary vascular resistance. Long-term right ventricular (RV) overload leads to RV dysfunction and failure, which are...

Cite
Alencar AKN, Montes GC, Barreiro EJ, et al. Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Front Pharmacol. 2017;8:858doi: 10.3389/fphar.2017.00858.
Alencar, A. K. N., Montes, G. C., Barreiro, E. J., Sudo, R. T., & Zapata-Sudo, G. (2017). Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Frontiers in pharmacology, 8858. https://doi.org/10.3389/fphar.2017.00858
Alencar, Allan K N, et al. "Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension." Frontiers in pharmacology vol. 8 (2017): 858. doi: https://doi.org/10.3389/fphar.2017.00858
Alencar AKN, Montes GC, Barreiro EJ, Sudo RT, Zapata-Sudo G. Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Front Pharmacol. 2017 Dec 04;8:858. doi: 10.3389/fphar.2017.00858. eCollection 2017. PMID: 29255415; PMCID: PMC5722832.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 117 entries